We advise our Life Sciences clients on their most complex, transformative deals
We leverage our deep understanding of the sector to provide our Life Sciences clients with integrated advice, enabling them to navigate their most important and challenging legal needs.
Many of the lawyers in our team have life sciences backgrounds and have experience working in the industry.
We offer clients a genuine interest and deep understanding of the sector, combined with integrated and dedicated advice to achieve clients’ objectives in ways which are commercially viable and practically achievable.
Our clients include companies active in pharmaceuticals, biotechnology and medical devices, as well as other organizations such as healthcare providers, regulatory authorities and academic institutions.
We help our clients address a wide range of issues across the life sciences industry, including:
- licenses and collaborations, joint ventures and other strategic alliances
- antitrust, competition and trade
- regulatory support
- litigation and arbitration
- intellectual property (IP)
We offer clients worldwide support from a broad and fully-integrated legal team, drawn from corporate, antitrust, IP, regulatory, litigation and product liability groups.
We also provide tax, employment and environmental support for clients.
AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals.
- on its portfolio transformation, including the asset swap with GSK (oncology, OTC and vaccines assets) and the sale of its animal health business to Eli Lilly.
- on the $5.2bn acquisition of Xiidra from Takeda/Shire.
- on all business aspects of the carve-out of its worldwide consumer healthcare business.
- on the €20bn asset swap (consumer health division swapped for animal health) with Sanofi.
Merck KGaA on its €3.4bn carve-out and divestment of its consumer health business to Procter & Gamble.
Johnson & Johnson on the global merger control aspects of its $30bn acquisition of Swiss biotechnology company Actelion Pharmaceuticals.
Bristol-Myers Squibb in relation to enforcing the patents relating to anti-PD1 antibodies for treating cancer in pan-European legal actions, one of the first major innovator– innovator patent disputes in Europe.
Advent on its €1.9bn acquisition of Zentiva, Sanofi’s European generics business (and on the add-on acquisition of Alvogen’s CEE business).
A global pharmaceutical company on investigations conducted by the DOJ regarding claims made under the US Federal Food, Drug and Cosmetic Act, the US False Claims Act and the US Anti-Kickback Act involving allegations of off-label promotion of prescription medications.
Shareholders of MYR GmbH on the sale of MYR GmbH (a German biotechnology) to Gilead Sciences, Inc. for approximately €1.15bn in cash plus a potential future milestone payment of up to €300 million.
Affimed N.V. on a licensing and strategic collaboration agreement with Roivant Sciences ($60 million upfront consideration plus up to $2 billion over time upon achievement of certain milestones and tiered royalty payments).
Vinita Kailasanath Partner
Mary Lehner Partner
Kristen O. Riemenschneider Partner
Paul Humphreys Partner
Doru Gavril Partner
Aimen Mir Partner
Eric Mahr Joint Head – Global Antitrust Litigation Group
Maj Vaseghi Partner
Peter D. Lyons Senior Counsel
Boris Feldman Partner, Head of U.S. Technology
Dr. Jochen Dieselhorst Partner
Richard Bird Partner
Marcel Kaufmann Partner
Dr. Frank-Erich Hufnagel Partner
Julian Long Partner
Simon Priddis Partner
Gwen Senlanne Partner
Dr. Heiner Braun Partner
Frankfurt am Main
Dr. Michael Ramb Partner